Buprenorphine diffusion: the attitudes of substance abuse treatment counselors.
In October 2002, the Food and Drug Administration approved buprenorphine for use in the treatment of opioid dependence. Successful diffusion, adoption, and implementation of this medication within the treatment field depend in part on substance abuse counselors. Using questionnaire data obtained from 2,298 counselors in community-based treatment programs in the private and public sectors between June 2002 and July 2004, we explored the diffusion of this new treatment technique. Analyses indicate that a substantial proportion of the clinical workforce is unaware of the effectiveness of buprenorphine in the treatment of opiate addiction. Several variables predicted counselors' attitudes toward buprenorphine. Predictors included receipt of buprenorphine-specific training, educational attainment, years of experience, and 12-step orientation. Implications for the diffusion of this and other emerging treatment techniques are discussed.
Knudsen
Hannah K
HK
Center for Research on Behavioral Health and Human Services Delivery, The University of Georgia, 101 Barrow Hall, Athens, GA 30602-2401, USA. hknudsen@uga.edu
Ducharme
Lori J
LJ
Roman
Paul M
PM
Link
Tanja
T
D001290:Attitude; D002047:Buprenorphine / Q000627:therapeutic use*; D003376:Counseling; D005260:Female; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy*
D009292:Narcotic Antagonists; D002047:Buprenorphine